NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

AGEN

Agenus Inc

May 16 • 04:00PM ET

3.48

Dollar change +0.10
Percentage change 2.96	%

Healthcare • Biotechnology • USA • NASD

Peers: BMY MRK PFE GILD JNJ AMGN VRTX REGN BIIB LLY

| Held by: IWM VTI VXF IWN VTWO IWO VHT IWC RSSL VTWV

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-8.68	Insider Own	3.81%	Shs Outstand	26.56M	Perf Week	19.59%
Market Cap	95.41M	Forward P/E	-	EPS next Y	-2.76	Insider Trans	0.00%	Shs Float	26.37M	Perf Month	110.91%
Income	-190.81M	PEG	-	EPS next Q	-0.98	Inst Own	31.39%	Short Float	15.37%	Perf Quarter	-0.85%
Sales	99.52M	P/S	0.96	EPS this Y	74.83%	Inst Trans	-6.22%	Short Ratio	6.48	Perf Half Y	12.08%
Book/sh	-12.87	P/B	-	EPS next Y	-3.43%	ROA	-83.45%	Short Interest	4.05M	Perf Year	-67.48%
Cash/sh	0.67	P/C	5.16	EPS next 5Y	35.25%	ROE	-	52W Range	1.38 - 19.69	Perf YTD	27.01%
Dividend Est.	-	P/FCF	-	EPS past 5Y	7.90%	ROI	-	52W High	-82.32%	Beta	1.43
Dividend TTM	-	Quick Ratio	0.11	Sales past 5Y	30.58%	Gross Margin	86.25%	52W Low	152.17%	ATR (14)	0.33
Dividend Ex-Date	-	Current Ratio	0.11	EPS Y/Y TTM	31.19%	Oper. Margin	-105.36%	RSI (14)	66.74	Volatility	13.33% 14.55%
Employees	316	Debt/Eq	-	Sales Y/Y TTM	-38.34%	Profit Margin	-191.72%	Recom	2.60	Target Price	6.33
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	65.97%	Payout	-	Rel Volume	1.32	Prev Close	3.38
Sales Surprise	9.48%	EPS Surprise	37.73%	Sales Q/Q	-14.07%	Earnings	May 12 BMO	Avg Volume	625.82K	Price	3.48
SMA20	14.53%	SMA50	53.76%	SMA200	-3.91%	Trades		Volume	824,183	Change	2.96%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-19-24	Downgrade	Robert W. Baird	Outperform → Neutral	$35 → $8
Jul-18-24	Downgrade	William Blair	Outperform → Mkt Perform
Jul-18-24	Downgrade	H.C. Wainwright	Buy → Neutral	$9
Jun-06-23	Initiated	Robert W. Baird	Outperform	$8
Jun-06-23	Initiated	Robert W. Baird	Outperform	$60 → $80
Feb-28-23	Resumed	H.C. Wainwright	Buy	$8
Sep-28-22	Initiated	SMBC Nikko	Outperform	$5
Dec-16-21	Initiated	H.C. Wainwright	Buy	$12
Nov-19-19	Resumed	B. Riley FBR	Buy	$6
Apr-22-19	Initiated	B. Riley FBR	Buy
Oct-28-16	Downgrade	H.C. Wainwright	Buy → Neutral	$10 → $5
Oct-27-16	Reiterated	Maxim Group	Buy
Mar-11-16	Upgrade	Maxim Group	Hold → Buy	$7
Dec-16-15	Initiated	Jefferies	Buy
Oct-27-15	Downgrade	Maxim Group	Buy → Hold
Jul-27-15	Reiterated	MLV & Co	Buy	$9 → $11
Jun-11-15	Initiated	Oppenheimer	Outperform	$14
Jan-12-15	Reiterated	Maxim Group	Buy	$10 → $11
Jan-09-15	Reiterated	MLV & Co	Buy	$6 → $9
Jan-09-15	Reiterated	Maxim Group	Buy	$10 → $11

Show Previous Ratings

May-16-25 10:45AM	Agenus says expanded MSS mCRC cohort data to be presented at ESMO GI (TipRanks)
May-15-25 10:40AM	Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025 (Business Wire)
08:42AM	AbbVie Secures FDA Nod for New ADC Drug Emrelis in Lung Cancer (Zacks)
May-14-25 06:29AM	Allogene's Q1 Earnings In Line With Estimates, Sales Nil (Zacks)
May-13-25 03:03AM	Agenus Inc (AGEN) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial Challenges (GuruFocus.com)
02:57AM	Loading…
02:57AM	Q1 2025 Agenus Inc Earnings Call (Thomson Reuters StreetEvents)
May-12-25 08:50AM	Agenus (AGEN) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +20.27%
07:47AM	Agenus: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Agenus Reports Q1 2025 Financial Results and Key Business Updates (Business Wire)
07:20AM	Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer (Business Wire)
May-09-25 09:47AM	Agenus Inc (AGEN) Q1 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
09:40AM	Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year? (Zacks)
May-08-25 09:25AM	MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates (Zacks)
May-07-25 06:15PM	Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
12:42PM	Waters Q1 Earnings Surpass Estimates, Revenue Rise Y/Y (Zacks)
05:15PM	Loading…
May-05-25 05:15PM	Vertex Pharmaceuticals (VRTX) Misses Q1 Earnings and Revenue Estimates (Zacks)
Apr-29-25 10:01AM	Agenus (AGEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
07:30AM	Agenus to Provide Corporate Update and First Quarter 2025 Financial Report (Business Wire)
Apr-28-25 03:30PM	Agenus BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR (Business Wire) +16.30%
Apr-25-25 01:05PM	Agenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025 (Business Wire)
Apr-23-25 12:05PM	Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025 (Business Wire)
09:40AM	Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year? (Zacks)
Apr-10-25 08:52AM	Abbott's Q1 Earnings Coming Up, Medical Devices Arm in Focus (Zacks) -6.09%
Mar-25-25 04:40PM	Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025 (Business Wire)
09:55AM	Here's Why Agenus (AGEN) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Mar-19-25 07:30AM	Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation (Business Wire)
Mar-12-25 03:03AM	Agenus Inc (AGEN) Q4 2024 Earnings Call Highlights: Strategic Moves Amid Financial Challenges (GuruFocus.com) -9.02%
01:35AM	Q4 2024 Agenus Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-11-25 11:45AM	Agenus (AGEN) Q4 2024 Earnings Call Transcript (Motley Fool)
08:40AM	Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:43AM	Loading…
07:43AM	Agenus: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program (Business Wire)
Feb-26-25 04:48PM	Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications (Business Wire) -8.63%
Feb-25-25 02:30PM	Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference (Business Wire)
08:26AM	Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report (Business Wire)
Feb-24-25 08:33AM	Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting (Business Wire)
Feb-23-25 07:38PM	CORRECTING and REPLACING Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting (Business Wire)
Feb-21-25 09:40AM	Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Feb-06-25 08:50AM	Agenus (AGEN) Is Attractively Priced Despite Fast-paced Momentum (Zacks)
Feb-05-25 09:40AM	Are Medical Stocks Lagging Agenus (AGEN) This Year? (Zacks) +11.43%
Jan-29-25 12:37PM	Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas (Business Wire)
Jan-22-25 02:48PM	Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease (Business Wire)
Jan-20-25 12:00PM	What Makes Agenus (AGEN) a New Buy Stock (Zacks)
09:40AM	Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Dec-18-24 07:30AM	Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers (Business Wire) -8.12%
Dec-06-24 06:07AM	AstraZeneca, Daiichi build cancer drug case; Amgen invests $1B (BioPharma Dive) +14.01%
Dec-05-24 07:30AM	Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs (Business Wire) -8.45%
Nov-27-24 10:20AM	Agenus Gets $22M Mortgage, Plans Strategic Realignment To Focus On Colorectal Cancer Drug Development (Benzinga)
08:15AM	Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment (Business Wire)
Nov-19-24 09:35AM	Agenus (AGEN) Loses -41.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Nov-18-24 09:35AM	Agenus (AGEN) Loses -41.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Nov-15-24 09:35AM	Down -39.39% in 4 Weeks, Here's Why Agenus (AGEN) Looks Ripe for a Turnaround (Zacks)
Nov-13-24 02:18AM	Q3 2024 Agenus Inc Earnings Call (Thomson Reuters StreetEvents)
02:08AM	Agenus Inc (AGEN) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges While ... (GuruFocus.com)
Nov-12-24 12:15PM	Agenus (AGEN) Q3 2024 Earnings Call Transcript (Motley Fool) -20.38%
08:20AM	Agenus (AGEN) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:19AM	Agenus: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development (Business Wire)
Nov-11-24 07:24AM	Earnings To Watch: Agenus Inc (AGEN) Reports Q3 2024 Result (GuruFocus.com)
Nov-07-24 10:00AM	Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024 (Business Wire) -6.87%
07:00AM	Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance (Business Wire)
Nov-05-24 07:30AM	Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update (Business Wire)
Nov-01-24 05:45AM	Investors in Agenus Inc. Should Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your Rights - AGEN (PR Newswire)
Oct-29-24 05:45AM	Investors in Agenus Inc. Should Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your Rights - AGEN (PR Newswire)
Sep-19-24 01:31PM	Agenus Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your Rights AGEN (GlobeNewswire)
Sep-17-24 05:45AM	Agenus Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your Rights - AGEN (PR Newswire)
Sep-16-24 12:51PM	Agenus Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your Rights AGEN (GlobeNewswire)
Sep-13-24 10:00AM	Botensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024 (Business Wire) +5.56%
Sep-09-24 07:30AM	Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024 (Business Wire)
Sep-03-24 07:30AM	Agenus to Participate in September Investor Conferences (Business Wire)
Aug-08-24 04:15PM	Agenus (AGEN) Q2 2024 Earnings Call Transcript (Motley Fool)
08:10AM	Agenus (AGEN) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:08AM	Agenus: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Agenus Reports Second Quarter 2024 Operational and Financial Results (Business Wire)
07:00AM	Agenus Announces Appointment of Tom Harrison to Board of Directors (Business Wire)
Aug-07-24 10:58AM	Agenus Publishes Seminal Study on Botensilimabs Activity in Treatment-Resistant Cancers (Business Wire) -6.45%
Aug-05-24 02:31PM	Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus (Benzinga) -6.93%
07:23AM	Bristol Myers sends TIGIT drug back to Agenus (BioPharma Dive)
Aug-01-24 10:01AM	Agenus (AGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-26-24 07:00AM	Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update (Business Wire) +9.97%
Jul-19-24 10:39AM	Agenus (AGEN) Tanks on Colorectal Cancer Study Interim Data (Zacks) -17.95%
07:47AM	Lilly alone in bidding for Morphic; Novartis wont yet file MorphoSys drug (BioPharma Dive)
Jul-18-24 07:00AM	Agenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal Cancer (Business Wire) -58.83%
Jun-28-24 11:10AM	Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI Conference (Business Wire) +18.63%
Jun-27-24 07:30AM	Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies (Business Wire)
Jun-17-24 07:00AM	Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors (Business Wire) -7.50%
Jun-13-24 05:15AM	Nature Medicine Reports Agenus Novel Immunotherapy Demonstrates Clinical Activity Against a Deadly Form of Colorectal Cancer on the Rise in Americans Under 50 (Business Wire) -5.44%
Jun-04-24 07:30AM	Agenus Announces Virtual Annual Shareholders Meeting (Business Wire)
May-30-24 03:30PM	Medical Moonshots: 3 Biotech Stocks Set to Skyrocket (InvestorPlace)
May-27-24 12:32PM	7 Biotech Stocks to Put on Your Breakthrough Radar (InvestorPlace)
May-24-24 05:00PM	Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +10.28% +11.97%
May-23-24 05:10PM	Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting (Business Wire)
07:30AM	Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
May-22-24 07:30AM	3 Magnificent Growth Stocks to Buy Hand Over Fist (Motley Fool) +7.10%
May-16-24 07:30AM	FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer (Business Wire)
May-08-24 01:22PM	Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript (Insider Monkey)
11:11AM	Agenus Inc. (NASDAQ:AGEN) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:09AM	Agenus Inc (AGEN) Q1 2024 Earnings Call Transcript Highlights: Strategic Developments and ... (GuruFocus.com)
May-07-24 05:45PM	Agenus (AGEN) Q1 2024 Earnings Call Transcript (Motley Fool) -7.26%
01:52PM	Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading (MT Newswires)

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AGEN

Agenus Inc

Upgrade your FINVIZ experience